Figure 4From: T/L-type calcium channel blocker reduces the composite ranking of relative risk according to new KDIGO guidelines in patients with chronic kidney disease Changes in details of the KDIGO 2009 categories at baseline and after CCB treatment. In (A) the amlodipine group and (B) the benidipine group. * P < 0.001 vs. at baseline.Back to article page